IE
GPCR icon

Israel Englander’s Structure Therapeutics GPCR Stock Holding History

Israel Englander’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.81M Sell
89,568
-79,363
-47% -$3.51M ﹤0.01% 3031
2026
Q1 		$8.14M Buy
168,931
+16,371
+11% +$1.12M ﹤0.01% 2379
2025
Q4 		$10.6M Sell
152,560
-1,121,991
-88% -$45.8M ﹤0.01% 2204
2025
Q3 		$35.7M Buy
1,274,551
+54,496
+4% +$1.09M 0.02% 1112
2025
Q2 		$25.3M Buy
1,220,055
+429,896
+54% +$9.45M 0.01% 1356
2025
Q1 		$13.7M Buy
790,159
+39,146
+5% +$959K 0.01% 1880
2024
Q4 		$20.4M Sell
751,013
-160,438
-18% -$5.69M 0.01% 1500
2024
Q3 		$40M Sell
911,451
-227,841
-20% -$8.81M 0.02% 977
2024
Q2 		$44.7M Buy
1,139,292
+1,048,350
+1,153% +$43M 0.02% 876
2024
Q1 		$3.9M Buy
90,942
+74,173
+442% +$3.13M ﹤0.01% 3123
2023
Q4 		$684K Sell
16,769
-283,105
-94% -$16.2M ﹤0.01% 4443
2023
Q3 		$15.1M Buy
299,874
+255,648
+578% +$8.24M 0.01% 1671
2023
Q2 		$1.84M Buy
44,226
+8,767
+25% +$246K ﹤0.01% 3559
2023
Q1 		$844K Buy
+35,459
New +$833K ﹤0.01% 4247

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Israel Englander's GPCR Position: Q2 2026 in Review

Israel Englander reduced its Structure Therapeutics (GPCR) stake by 47% in Q2 2026, selling an estimated $3.51M and leaving 89,568 shares worth $4.81M. The position accounts for ﹤0.01% of the portfolio, ranked #3031.

Israel Englander first reported a position in GPCR in Q1 2023 and has held it in 14 quarters since. The position peaked at $44.7M in Q2 2024. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Israel Englander held 89,568 shares of Structure Therapeutics worth $4.81M as of Q2 2026.
  • Israel Englander sold 79,363 Structure Therapeutics shares in Q2 2026, an estimated $3.51M.
  • Structure Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3031 holding.
  • Israel Englander first reported a position in Structure Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Israel Englander's Structure Therapeutics position peaked at $44.7M in Q2 2024.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.